Esperion Therapeutics ESPR R&D credit carryforward
R&D credit carryforward at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.
The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's r&d credit carryforward.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's r&d credit carryforward?
- Esperion Therapeutics (ESPR) reported r&d credit carryforward of $18.89M in Q4 2025.
- How has Esperion Therapeutics's r&d credit carryforward changed year-over-year?
- Esperion Therapeutics's r&d credit carryforward decreased by 0.0% year-over-year, from $18.89M to $18.89M.
- What is the long-term trend for Esperion Therapeutics's r&d credit carryforward?
- Over 5 years (2020 to 2025), Esperion Therapeutics's r&d credit carryforward has grown at a -4.2% compound annual growth rate (CAGR), from $23.45M to $18.89M.
- What does r&d credit carryforward mean?
- This represents the accumulated value of research and development tax credits that have not yet been utilized to offset tax liabilities. These carryforwards provide a future tax benefit that can be applied against taxable income in subsequent periods. It is a key indicator of the company's historical investment in R&D and its potential to lower future effective tax rates.